Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.780
-0.040 (-2.20%)
At close: Sep 26, 2025, 4:00 PM EDT
1.820
+0.040 (2.25%)
After-hours: Sep 26, 2025, 4:00 PM EDT
Innate Pharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Innate Pharma stock has a target of 2.00, which predicts a 12.36% increase from the current stock price of 1.78.
Price Target: $2.00 (+12.36%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Innate Pharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $2 | Buy → Hold | Downgrades | $10 → $2 | +12.36% | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 → $11 | Strong Buy | Reiterates | $12 → $11 | +517.98% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +546.07% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +546.07% | Feb 6, 2025 |
Financial Forecast
Revenue This Year
90.74M
from 20.12M
Increased by 350.96%
Revenue Next Year
120.61M
from 90.74M
Increased by 32.92%
EPS This Year
0.42
from -0.61
EPS Next Year
0.32
from 0.42
Decreased by -23.23%
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 193.2M | 302.4M | |||
| Avg | 90.7M | 120.6M | |||
| Low | 12.7M | 6.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 860.2% | 233.3% | |||
| Avg | 351.0% | 32.9% | |||
| Low | -37.0% | -92.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.41 | 1.88 | |
| Avg | 0.42 | 0.32 | |
| Low | -0.55 | -0.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 351.1% | |
| Avg | - | -23.2% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.